Panacea Biotec granted patent in India for Willgo osteoarthritis drug

By Lisa Kerner

Charlotte, N.C., Aug. 7 - Panacea Biotec Ltd. said the Indian government has granted the company a 20-year patent for its extended-release pharmaceutical composition containing nimesulide, one of the most widely prescribed non-steroidal anti-inflammatory drugs.

The company launched its extended-release nimesulide product under the brand name Willgo in India in 2004.

Once-daily Willgo relieves joint pain, stiffness, swelling and tenderness in patients with osteoarthritis.

Panacea Biotic is a health-management company based in New Delhi, India.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.